



Flexion Therapeutics, Inc.
Investor Relations Department
10 Mall Road
Suite 301
Burlington, MA 01803
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

| | |
|---------------|--|
| Last Trade: | 26.32 |
| Trade Time: | 12:59 PM ET Nov 24, 2017 |
| Change: | 2.83 ▲ (+12.048%) |
| Day Range | 23.90 - 26.34 |
| 52-Week Range | 15.96 - 32.25 |
| Volume | 1,523,858 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 20, 2017 [Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\)](#)
- Nov 17, 2017 [Flexion Therapeutics Named Top Place to Work for 2017 by The Boston Globe](#)
- Nov 6, 2017 [Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights](#)
- Nov 2, 2017 [Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting](#)
- Oct 30, 2017 [Flexion Therapeutics to Report Third-Quarter 2017 Financial Results on November 6, 2017](#)

Upcoming Events [\[View all \]](#)

- Dec 14, 2017 8:30 AM ET [BMO Capital Markets: Prescriptions for Success Healthcare Conference](#)
- Third Quarter Financial Results
- Mar 10, 2017 [Annual Report \(10-K\)](#)
- Apr 28, 2017 [Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 8, 2017 [Quarterly Report \(10-Q\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)